LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Закрыт

СекторЗдравоохранение

11.37 -6.42

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

11.11

Макс.

11.6

Ключевые показатели

By Trading Economics

Доход

1.4M

676K

Продажи

961K

18M

P/E

Средняя по отрасли

48.528

110.024

Прибыль на акцию

-0.034

Дивидендная доходность

0.48

Рентабельность продаж

3.67

Сотрудники

212

EBITDA

-3M

2.3M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+62.95% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.48%

2.26%

Следующий отчет о доходах

2 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-120M

248M

Предыдущая цена открытия

17.79

Предыдущая цена закрытия

11.37

Новостные настроения

By Acuity

50%

50%

149 / 351 Рейтинг в Healthcare

Simulations Plus Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 февр. 2026 г., 22:36 UTC

Отчет

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 февр. 2026 г., 22:32 UTC

Отчет

Woodside Energy Fiscal Year Net Profit Falls 24%

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Global Energy Roundup: Market Talk

23 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 февр. 2026 г., 23:43 UTC

Обсуждения рынка

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 февр. 2026 г., 23:41 UTC

Приобретения, слияния, поглощения

Crescent Capital Partners Owns 53% of ClearView Wealth

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 февр. 2026 г., 23:40 UTC

Обсуждения рынка

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 февр. 2026 г., 23:39 UTC

Приобретения, слияния, поглощения

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 февр. 2026 г., 23:27 UTC

Отчет

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 февр. 2026 г., 23:24 UTC

Обсуждения рынка

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 февр. 2026 г., 22:38 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 февр. 2026 г., 22:31 UTC

Отчет

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 февр. 2026 г., 22:24 UTC

Отчет

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Underlying Ebitda A$700.9 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 февр. 2026 г., 22:20 UTC

Отчет

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение c конкурентами

Изменение цены

Simulations Plus Inc Прогноз

Целевая цена

By TipRanks

62.95% рост

Прогноз на 12 месяцев

Средняя 19 USD  62.95%

Максимум 19 USD

Минимум 19 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Simulations Plus Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

4 ratings

2

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

149 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat